Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia

Leuk Lymphoma. 2020 Apr;61(4):855-861. doi: 10.1080/10428194.2019.1691195. Epub 2019 Nov 22.


Chidamide, a novel histone deacetylase inhibitor, has exerted effects in T-cell tumors through various mechanisms. Seventeen patients with refractory or relapsed T-cell acute lymphoblastic lymphoma/leukemia (T-LBL/ALL) received Chidamide combined with chemotherapy as salvage treatment. Historical data was analyzed as comparison as chemotherapy group. Complete response (CR) rate and overall response rate (ORR) of Chidamide + chemotherapy group were higher than that of chemotherapy group after one course. Chidamide + chemotherapy group had a better progress-free survival (PFS) compared to chemotherapy group. No difference in overall survival (OS) was observed. Grade 3/4 nonhematological adverse events (>10%) of patients in Chidamide + chemotherapy group included febrile neutropenia (64.7%), drug-induced liver failure (17.6%), decreased fibrinogen (11.8%), sepsis (11.8%), pneumonitis (11.8%), and oral mucositis (11.8%). This study demonstrates that Chidamide included regimen may be a new treatment strategy with an acceptable safety profile for refractory or relapsed T-LBL/ALL patients but requires further investigation.

Keywords: Chidamide; Precursor T-cell lymphoblastic leukemia-lymphoma; early T-cell precursor acute lymphoblastic lymphoma/leukemia; hematopoietic stem cell transplantation; salvage therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Benzamides
  • Humans
  • Lymphoma, Non-Hodgkin*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy


  • Aminopyridines
  • Benzamides
  • N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide